Search results
Pfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027
Reuters via Yahoo Finance· 2 days agoInvestors have fled from Pfizer as pandemic worries declined and billions of dollars in COVID-19...
Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027
Zacks via Yahoo Finance· 1 day agoThis is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first...
Pfizer (NYSE:PFE) Shares Up 2%
ETF DAILY NEWS· 7 hours agoPfizer Inc. (NYSE:PFE – Get Free Report)’s share price was up 2% during trading on Wednesday . The stock traded as high as $29.18 and last traded at $29.13. Approximately ...
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Benzinga via Yahoo Finance· 4 days agoA Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc...
Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027 - Pfizer (NYSE:PFE)
Benzinga· 1 day agoPfizer Inc. PFE has launched a multi-year cost-cutting initiative aimed at saving approximately $1.5...
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Zacks via Yahoo Finance· 4 hours agoAstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer...
Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts
CNBC· 2 days agoPfizer on Wednesday said it has launched a new multi-year program to reduce costs as it works to...
Pfizer's Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions - ...
Benzinga· 24 hours agoPfizer Inc. PFE has recently launched a multi-year cost reduction initiative aimed at saving...
3 Stocks That Can Help You to Get Richer in 2025 and Beyond
Motley Fool via Yahoo Finance· 5 hours ago(The long-term annual average return of the S&P 500 is around 10%.) If you're looking for very...
Pfizer shares the ADC data that convinced it to start a Phase 3 lung cancer trial
Endpoints News· 20 hours agoWhen Pfizer laid out the ambitious vision for its new oncology division in February, it announced...